Teva to move U.S. home base to Parsippany-Troy Hills, N.J.
Israeli-based Teva will be moving its U.S. home base to Parsippany-Troy Hills from North Wales, Pa. New Jersey Governor Phil Murphy announced the move, which will transfer and create a total of 843 jobs in the state, while 232 workers at the Parsippany-Troy Hills location — which will expand to nearly 350,000 square feet — will keep their positions.
Teva will become neighbors with several major pharma players that are based in New Jersey, including Merck, Bristol-Myers Squibb and Johnson & Johnson.
The decision follows approval of a 10-year, $40 million tax incentive plan that was designed to lure Teva to the Garden State. The plan required Teva to keep 1,000 New Jersey jobs to reap the credits.
The move will help Teva, which is in the middle of a $3 billion cost-cutting effort mapped out by new CEO Kåre Schultz, consolidate some of its operations in a central location, said the FiercePharma report.
“Reducing the number of sites supports our drive to continue to improve productivity and efficiencies,” Teva EVP and head of North American commercial Brendan O’Grady said in a statement. “We’re pleased to expand our presence in New Jersey, having closer proximity to a vibrant business hub and a dynamic life sciences environment—all while increasing jobs and preserving many existing roles.”
O’Grady said the company would “retain a significant presence” in Pennsylvania.
In January, 65 employees across three buildings in Horsham and North Wales, Pennsylvania, 96 across sites in Fraser and Great Valley, and 47 more in West Chester lost their jobs.
Two senators urge GSK to end Shingrix shingles vaccine shortage
Although GlaxoSmithKline said it has developed a “fair and equitable” process to ship Shingrix, its new shingles vaccine, two U.S. senators are urging the drugmaker do more to increase inventory levels in the wake of a shortage, according to a FiercePharma report.
As of May, more than 1.5 million people have received the vaccine.
Minnesota Sens. Amy Klobuchar and Tina Smith wrote to GSK CEO Emma Walmsley asking that she look at “what more GSK can do to end the shortage as quickly as possible.” The senators said it appears that GSK didn’t develop “contingency plans” to ensure enough supply for the important vaccine launch. The senators voiced concern that patients may not be able to complete their recommended schedule of two doses in six months.
In an update with CBS in Minnesota, Sen. Klobuchar said GSK plans to meet with her.
After GSK received approval for Shingrix last fall, the Centers for Disease Control and Prevention vaccine advisers recommended Shingrix above Merck’s older Zostavax, which may be one of the reasons the vaccine is in short supply, said the FiercePharma report.
GSK has set up order limits and delays to manage doses, and has delayed such “broad consumer education activities” as TV ads until it can restore inventory levels.
NACDS, APhA and ACOG team up on immunization tip sheet
Industry stakeholders recently came together to help develop a resource for obstetricians and gynecologists to create an immunization referral system that includes pharmacists. The National Association of Chain Drug Stores worked with the American College of Gynecologists and the American Pharmacists Association to create a tip sheet for clinicians looking to establish a referral system.
NACDS said that both obstetrician-gynecologists and pharmacists, including those from NACDS member companies, helped develop the tip sheet that collects information to improve healthcare stakeholder collaboration and improve immunization rates. Such referral systems can play a key role in expanding and maintaining pharmacy-physician practice collaborations, the organization said.
The tip sheet can be found here.